Last updated: 2026-09-16 10:31:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Jazz Pharmaceuticals, Inc. (JAZZ) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $242.92, with a market capitalisation of $15.96B and a P/E ratio of 16.62. Over the past 52 weeks, its price has ranged from $124.47 to $266.38. This page covers its latest market performance, valuation, price trends and company information.
$15.96B | |
$243.00 | |
$266.38 | |
$0.52 | |
$240.83 | |
2.45K | |
876.27K | |
16.62 | |
$266.38 | |
$124.47 | |
-- | |
-- |
Jazz Pharmaceuticals, Inc. (JAZZ) is trading at $242.92 in pre-market trading as of 2026-09-16 10:28:00, up 0.87% ($2.08) from the previous close of $240.83
Pre-market trading shows how investors are pricing JAZZ before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Jazz Pharmaceuticals, Inc. (JAZZ) moved from $246.81 to $242.92, representing a decline of 1.58% ($3.90).
The stock traded between $236.00 and $249.00 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 547.81 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 83.5%
JAZZ is currently trading at $242.92, placing it 83.5% of the way from its 52-week low of $124.47 to its 52-week high of $266.38. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 2890 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Jazz Pharmaceuticals, Inc. (JAZZ) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.